ProQR Therapeutics (NASDAQ:PRQR) Downgraded by StockNews.com to Sell

ProQR Therapeutics (NASDAQ:PRQR) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

PRQR has been the topic of several other reports. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright boosted their price target on ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.13.

ProQR Therapeutics Stock Up 6.7 %

PRQR traded up $0.23 during trading on Thursday, hitting $3.67. The company’s stock had a trading volume of 416,651 shares, compared to its average volume of 522,656. ProQR Therapeutics has a twelve month low of $1.33 and a twelve month high of $4.62. The stock’s fifty day moving average price is $3.04 and its 200-day moving average price is $2.27. The firm has a market capitalization of $299.77 million, a P/E ratio of -11.47 and a beta of 0.26.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PRQR. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after acquiring an additional 236,279 shares in the last quarter. OneDigital Investment Advisors LLC increased its holdings in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).